News about Danaher

Danaher has announced a collaboration with NVIDIA combining its instruments, automation and software with NVIDIA's AI platforms, along with an AI-powered autonomous lab at Abcam for faster custom antibody development. The article links this push to future demand for more automated, data-rich research, but says it does not fundamentally change near-term risk-reward given China trade frictions and volume-based procurement. Analyst models already assume 8.1% annual revenue growth over three years and margin expansion from 15.9% to 19.3%, so the AI initiatives sit within existing expectations. Consensus sees profit rising from US$4.0b today to about US$6.1b by 2029, with the central target of US$236.32 against a US$214.06 share price. The mid case implies a P/E of about 34.1x on 2029 earnings, versus 37.7x today.